StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

Analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a research report on Wednesday, February 26th.

Minerva Neurosciences Trading Down 2.9 %

Shares of NERV stock opened at $1.81 on Wednesday. The firm has a fifty day simple moving average of $1.93 and a two-hundred day simple moving average of $2.24. Minerva Neurosciences has a 12 month low of $1.42 and a 12 month high of $3.69. The firm has a market capitalization of $12.66 million, a PE ratio of -4.11 and a beta of 0.10.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.49. On average, equities analysts predict that Minerva Neurosciences will post -0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Minerva Neurosciences stock. Northern Trust Corp raised its position in Minerva Neurosciences, Inc. (NASDAQ:NERV) by 60.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 36,878 shares of the biopharmaceutical company’s stock after buying an additional 13,829 shares during the period. Northern Trust Corp owned 0.53% of Minerva Neurosciences worth $82,000 as of its most recent filing with the SEC. 34.56% of the stock is currently owned by hedge funds and other institutional investors.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.